Option chain shows key data for Intensity Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Intensity Therapeutics.

Intensity Therapeutics (NASDAQ:INTS) Stock, Option Chain

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Wall Street

News

Initiation

Markets

Analyst Ratings

Trading Ideas

ALMS

BRZE

ELVN

INTS

TERN

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Penny Stocks

Small Cap

Intraday Update

Movers

ADBE

ADTX

ALEC

APLS

ASLE

ASYS

ATUS

BLND

CDXS

CPHC

CPTN

ENPH

ESPR

FRGT

HRYU

MIND

MRNA

MYND

NOVA

NXTC

NXTP

OCUL

OPEN

PACB

PLUG

RDFN

RILY

RPHM

SVMH

TPIC

VCIG

VIEW

Shares of Amtech Systems, Inc.  (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

AUVI

EKSO

NUBI

PHIO

SNOA

STTK

Shares of  Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors.

Nxu, shares rose 42.1% to $0.0278 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

Interactive Strength Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares are trading higher by 20% to $4.34 Thursday morning after the company <a href="https://www.benzinga.com/pressreleases/24/11/ac42108296/interactive-strength-inc-nasdaq-trnr-board-of-directors-approves-bitcoin-as-treasury-reserve-asse">announced plans</a> to integrate Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) into its financial strategy.
What Happened: The company&#8217;s Board of Directors has approved the purchase of up to $5 million in Bitcoin, subject to a cap of 25% of the company&#8217;s average daily cash holdings over the past three months.
Co-Founder and CEO Trent Ward highlighted Bitcoin&#8217;s appeal as an inflation-resistant asset and its growing acceptance among investors. 
Ward pointed to the rise of Bitcoin ETFs and increased institutional adoption as signals of the cryptocurrency&#8217;s mainstream viability. &#8220;Bitcoin&#8217;s potential as a store of value and hedge against inflation makes it a compelling addition to our treasury,&#8221; Ward stated.
Beyond investment, Interactive Strength plans to accept cryptocurrency payments for its products. The company will retain these payments in Bitcoin.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42107846/nvidia-slides-during-thursday-pre-market-despite-beating-q3-estimates-even-outstanding-isnt-enough-for-some-investors">Nvidia Slides During Thursday Pre-Market Despite Beating Q3 Estimates: &#8216;Even Outstanding Isn&#8217;t Enough For Some Investors&#8217;</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TRNR has a 52-week high of $4,760.00 and a 52-week low of $2.50.

$BTC

TRNR

Why Interactive Strength (TRNR) Stock Is Popping Off

Vonglis to help manage NANO Nuclear's key government relationships as it proceeds through the development and licensure process for its advanced microreactors, other nuclear technologies and services
New York, N.Y., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) ("NANO Nuclear" or "the Company"),&nbsp;a leading advanced nuclear energy and technology company focused on developing portable, clean energy solutions, today announced that the Hon. John G. Vonglis, former Chief Financial Officer of the U.S. Department of Energy (DOE), Acting Director of DOE's Advanced Research Projects Agency-Energy (APRA-E), and Chairman of NANO Nuclear's Executive Advisory Board for Strategic Initiatives has transitioned to an active corporate role within NANO Nuclear as its Executive Director of Global Government Affairs.
In his new role, Vonglis will play a vital role in strengthening relationships with key government agencies and policymakers, ensuring alignment between NANO Nuclear's goals and government priorities in encouraging and financing nuclear energy. His appointment is a key element in NANO Nuclear's management expansion strategy, which has attracted top financial, regulatory, and scientific leaders to NANO Nuclear in recent months. The assembled team of highly qualified and proven leaders positions NANO Nuclear to capitalize on the rising momentum in the industry, fueled by U.S. government support, growing public interest, and favorable capital market conditions.

Management

NANO Nuclear Energy Announces Former CFO Of The U.S. Department Of Energy John G. Vonglis Takes On Active Corporate Role As Executive Director Of Global Government Affairs

BJ&#8217;s Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) shares are trading higher in the<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> premarket session on Thursday.</a>
The company reported third-quarter adjusted earnings per share of $1.18, beating the street view of 91 cents. Quarterly revenues of $5.10 billion were in line with the analyst consensus.
Comparable club sales rose 1.5% year-over-year, with a 3.8% increase excluding gasoline. Digitally enabled comparable sales growth was 30.0%, reflecting two-year stacked comp growth of 47.0%.
Membership fees grew 8.4% to $115 million. Adjusted EBITDA gained by 13.5% to $308.292 million.
The company estimates that an increase in sales, temporarily driven by a port strike and hurricanes, had a favorable impact of slightly less than one percentage point on its third-quarter comparable club sales, excluding gasoline.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible" rel="noreferrer noopener">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a>
Merchandise gross margin rate increased by 20 basis points year over year, primarily driven by the continued execution of long-term initiatives and improved cost management.&nbsp;
&#8220;We expect fourth quarter fiscal 2024 comparable club sales, excluding the impact of gasoline sales, to increase 2.5% to 3.0% year-over-year, bringing the full year fiscal 2024 growth to between 2.3% and 2.4%,&#8221; said Laura Felice, Executive Vice President, Chief Financial Officer, BJ&#8217;s Wholesale Club.
The company exited the quarter with cash and equivalents worth $33.87 million and merchandise inventories of $1.72 billion. The company&#8217;s long-term debt stands at $398.66 million.
Outlook: BJ&#8217;s Wholesale Club expects fourth-quarter adjusted EPS to be between $0.78 and $0.88. For FY2024, adjusted EPS is forecasted at $3.90 &#8211; $4.00, up from previous guidance for a low end of $3.75 &#8211; $4.00 and <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">above the consensus estimate of $3.84.</a>
BJ&#8217;s Wholesale Club expects fourth quarter comparable club sales, excluding gasoline, to rise 2.5%-3.0% year-over-year.
On November 18, the company approved a new share repurchase program. The authorization allows the company to repurchase up to $1.0 billion of its outstanding common stock and will expire in January 2029.
Price Action: BJ shares are trading higher by 2.67% to $87.99 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly" target="_blank" rel="noreferrer noopener">Target Says Shoppers Wait For &#8216;Deals&#8217; A Day After Rival Walmart Credits Market Gains To Wealthy Households</a></li>
</ul>

Earnings

Equities

Guidance

Buybacks

General

BJ's Wholesale Q3: EPS Beat, Digital Boom, $1B Buyback Program & More

SCWorx Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares are trading higher by 66.3% to $1.63 Thursday morning after the company announced it has successfully regained compliance with <a href="https://www.benzinga.com/pressreleases/24/11/g42100357/scworx-announces-compliance-with-nasdaqs-periodic-reporting-listing-standard">Nasdaq's listing standards </a>for periodic reporting.
The compliance issue arose earlier this year when Nasdaq notified SCWorx on April 17, May 17 and August 19 that the company had fallen out of compliance with Listing Rule 5250(c)(1), which requires timely periodic filings.
The issue was resolved following the company's filing of its Form 10-K for the fiscal year ending December 31, 2023, and Forms 10-Q for the quarters ending March 31 and June 30. Nasdaq confirmed in a letter dated October 14, that SCWorx had met all filing obligations and closed the compliance matter.
Read Also: <a href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a>
SCWorx late Wednesday also announced it had completed an <a href="https://www.benzinga.com/pressreleases/24/11/g42099931/scworx-announces-completion-of-equity-financing-with-institutional-investors">equity financing</a> with institutional investors. 
In connection with the funding, the company sold an aggregate of 232,558 shares of common stock and warrants to purchase the same number of shares of common stock, for aggregate gross proceeds of $200,000.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WORX has a 52-week high of $4.44 and a 52-week low of $0.75.

WORX

Why SCWorx Stock Is Up 66% Today

SURG

SurgePays Announces Agreement With AT&T, Enabling SurgePays To Offer Mobile Wireless, Voice, Data And Messaging Services

Dan Ives, a prominent tech analyst, took to social media on Thursday to express his enthusiasm for&nbsp;Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) next-generation Blackwell chips. 
What Happened: Ives described the chips as &#8220;The LeBron of chip releases,&#8221; highlighting their rapid market ramp-up and absence of overheating issues, contrary to recent reports. He further characterized Nvidia&#8217;s earnings as a &#8220;press release that should be&nbsp;framed and hung in the&nbsp;Louvre.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The LeBron of chip releases, next generation Blackwell ramping even faster than expected with NO overheating issues and appears to be on a massive demand trajectory. We would characterize results as an earnings press release that should be framed and hung in the Louvre &#x1f3c6;&#x1f525;&#x1f37f;&#x1f402;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1859581580605362648?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite Ives&#8217; positive outlook, recent reports have indicated that <a href="https://www.benzinga.com/24/11/42103355/nvidias-blackwell-set-to-outpace-hopper-heres-what-ceo-jensen-huang-predicted-for-2025">Nvidia&#8217;s Blackwell AI chips</a> are facing overheating problems when integrated into server racks designed to accommodate up to 72 chips. The Information reported that Nvidia has requested suppliers to adjust rack designs to mitigate these issues. 
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42079954/microsoft-ceo-satya-nadella-defends-bings-rise-against-googles-search-dominance-says-openais-partnership-with-apple-is-incremental-for-even-us?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Satya Nadella Defends Bing&#8217;s Rise Against Google&#8217;s Search Dominance — Says OpenAI&#8217;s Partnership With Apple Is &#8216;Incremental&#8217; For Microsoft</a>
Why It Matters: The enthusiasm expressed by Ives comes at a crucial time for Nvidia. CEO Jensen Huang has predicted that Blackwell will <a href="https://www.benzinga.com/24/11/42028342/blackwell-backfires-nvidias-ai-chips-struggle-with-server-overheating-impacting-meta-microsoft-and-musks-xai-data-centers">surpass the company&#8217;s Hopper GPUs</a> in shipments by 2025, underscoring the strategic importance of these chips. Despite overheating concerns, Nvidia&#8217;s stock has shown resilience, even amid delays in Blackwell&#8217;s production and missed fourth-quarter whisper numbers, as noted by Gary Black, managing partner of The Future Fund.
Meanwhile, the chipmaker reported a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42107846/nvidia-slides-during-thursday-pre-market-despite-beating-q3-estimates-even-outstanding-isnt-enough-for-some-investors">94% year-over-year increase in revenue</a>, reaching $35.1 billion, exceeding the anticipated $33.12 billion. Additionally, the company's earnings per share were 81 cents, surpassing the projected 75 cents.
Despite these strong financial results, investor concerns arose due to a slowdown in sales compared to previous quarters. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42022443/ibm-disney-and-other-large-advertisers-return-to-elon-musks-x-after-a-year-long-boycott-we-super-appreciate?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">IBM, Disney And Other Large Advertisers Return To Elon Musk&#8217;s X After A Year-Long Boycott: &#8216;We Super Appreciate&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy of Nvidia

NVDA

Dan Ives Predicts Nvidia's Blackwell Chips Are Heading For 'Massive Demand Trajectory' As Jensen Huang Says 'LeBron Of Chip Releases' To Surpass Hopper GPU Shipments

Iterum Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has been cured and that the Company is in compliance with applicable continued listing requirements.
Based on the foregoing, the previously scheduled Nasdaq hearing before the Hearings Panel on November 21, has been cancelled. The Company will continue to be traded on The Nasdaq Capital Market.

ITRM

Iterum Therapeutics Regains Nasdaq Compliance

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD Holdings Executive Says We Have Seen An Overall Recovery In Consumption In The Second Half Of This Year; In Q3, The Release Of New Macroeconomic Policies In China Have Opened New Opportunities But Also New Challenges; To Stay Competitive, Co. Had To Incur 'Much Higher Costs Than Peers" Which Inevitably Impacts Profitability Now And Into The Future

WIIM

AAOI

Applied Optoelectronics shares are trading higher. The company filed a complaint for patent infringement against Eoptolink and is seeking monetary damages in the US district court for the northern district of California

Cantor Fitzgerald analyst C J Muse reiterates NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and maintains $175 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on NVIDIA, Maintains $175 Price Target

iCoreConnect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>) reported quarterly losses of $(0.61) per share. This is a 12.96 percent decrease over losses of $(0.54) per share from the same period last year. The company reported $2.79 million in sales this quarter. This is a 39.05 percent increase over sales of $2.00 million the same period last year.

ICCT

iCoreConnect Q3 EPS $(0.61) Down From $(0.54) YoY, Sales $2.79M Up From $2.00M YoY

DYAI

Dyadic Receives $3M Grant From Gates Foundation For Cell Line Development Of Monoclonal Antibodies For RSV And Malaria Using C1 Platform Technology

iCoreconnect Q3 Revenue $2.787M Up From $2.004M YoY

Vertically integrated cannabis company Cansortium Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TIUM#CSE">TIUM</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTCQB">CNTMF</a>), operating under the FLUENT brand, launched the cannabis concentrate line, Hyer Kind. The Tampa-based multi-state operator notes that the new product is exclusively available at all FLUENT dispensaries across Florida.
Hyer Kind offers cured badder, crumble, and cured resin cartridges designed to support wellness routines and address the increasing interest in concentrates among medical marijuana patients in the Sunshine State.
&#8220;As FLUENT's first brand dedicated exclusively to concentrates, Hyer Kind marks a key milestone for us," stated Robert Beasley, CEO of Cansortium. "We are so proud to be associated with a quality brand like Hyer Kind and know consumers in Florida will be happy that this offering is now available in our stores. From the whole flower selection to the extraction methods, we're on a mission to set a new standard for concentrates by prioritizing flavor, quality, innovation and accessibility. It's our responsibility to meet patients where they are by expanding our offerings and providing diverse price points to ensure everyone has access to the products that suit their needs."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41381476/riv-capital-partners-with-cannabis-wholesale-platform-nabis-to-boost-new-york-distribution">https://www.benzinga.com/markets/cannabis/24/10/41381476/riv-capital-partners-with-cannabis-wholesale-platform-nabis-to-boost-new-york-distribution</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
Hyer Kind products are developed to provide full-spectrum flavor derived from cannabis plants. The process involves selecting whole flowers and using hydrocarbon and solventless extraction techniques. Methods like live ice-water extraction are employed to maintain quality and potency for medical marijuana patients.
With plans to expand Hyer Kind into additional markets, including New York, its cured badder and resin cartridges (0.5g) are available exclusively to Florida patients for $50, with crumble priced at $45. FLUENT also plans to expand the brand's portfolio with additional concentrate options.
In October, the New York Cannabis Control Board <a href="https://www.benzinga.com/markets/cannabis/24/10/41282624/major-cannabis-merger-approved-in-new-york-can-weed-stock-investors-take-advantage">approved the merger</a> between Cansortium and RIV Capital. The merger, expected to close by the end of 2024, positions the combined company to take full advantage of<a href="https://www.benzinga.com/markets/cannabis/24/05/39094250/this-cannabis-merger-will-cover-25-of-u-s-population-cansortium-riv-capital-powered-by-scottsmir" target="_blank" rel="noreferrer noopener"> covering 25% of the U.S. population</a> with eight cultivation and processing facilities and 42 retail dispensaries.
Price Action
Cansortium shares closed Wednesday's market session 5.26% lower at $0.900 per share.
Read Next
<ul>
<li><a href="https://www.benzinga.com/news/retail-sales/24/11/42098974/canopy-growth-aurora-and-another-cannabis-giant-unveil-product-innovations-heres-whats-new">Canopy Growth, Aurora And Another Cannabis Giant Unveil Product Innovations, Here&#8217;s What&#8217;s New</a></li>
</ul>
Photo: Courtesy of fukume via Shutterstock,

Cannabis

Exclusives

CNTMF

CSE:TIUM

FLUENT Launches New Cannabis Concentrates Line For Medical Marijuana Patients In Florida

BYON

The Container Store Expects SPA Conditions With Beyond Inc. To Remain Unsatisfied; Pursues Additional Capital From Existing Lenders To Support Long-Term Growth And Strategic Initiatives

A Chinese state-backed company, Spacesail, is preparing to launch a satellite service in Brazil, posing a challenge to Elon Musk&#8216;s SpaceX operated satellite service, Starlink. This announcement aligns with Chinese President Xi Jinping&#8216;s visit to Brazil, where he signed an upgraded partnership with President Luiz Inácio Lula da Silva on Thursday.
What Happened: Spacesail, which specializes in&nbsp;high-speed internet services through low&nbsp;Earth orbit satellites, has teamed up with Brazilian state-owned&nbsp;Telebrás&nbsp;to offer&nbsp;satellite communications and broadband Internet&nbsp;services. The companies plan to evaluate demand in regions lacking fiber optic infrastructure, with the service expected to launch by 2026, according to a spokesperson from Brazil&#8217;s communications ministry.
This move comes amid tensions between Musk&#8217;s SpaceX and Brazilian authorities over alleged misinformation on Musk&#8217;s social media platform, X. Starlink, which controls nearly half of Brazil&#8217;s satellite internet market, was recently fined for failing to comply with court orders to remove extremist content. 
See Also: <a href="https://www.benzinga.com/news/24/11/42025443/elon-musk-reacts-after-brazilian-presidents-wife-swears-at-tesla-ceo-they-will-lose-the-next-lection?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Brazilian President&#8217;s Wife Swears At Tesla CEO: &#8216;They Will Lose The Next Election&#8217;</a>
This development occurs as the U.S. expresses concerns over China&#8217;s increasing influence in Latin America, a region traditionally dominated by Washington. Spacesail plans to deploy 15,000 satellites by 2030, having already launched 36 satellites this year,&nbsp;according to Chinese state media.
Why It Matters: The entry of Spacesail into the Brazilian market is part of a<a href="https://www.benzinga.com/news/24/08/40210259/china-challenges-elon-musks-spacex-starlink-with-its-own-internet-satellites-plans-to-deploy-648-sat"> broader strategy by China</a> to expand its satellite internet capabilities globally. In August, China launched its Thousand Sails project, aiming to deploy over 15,000 low-Earth orbit satellites to provide worldwide internet coverage. This initiative is seen as a direct challenge to Musk&#8217;s Starlink.
Meanwhile, Starlink has faced <a href="https://www.benzinga.com/news/24/09/40680467/after-x-ban-elon-musks-starlink-defies-brazilian-court-order-to-block-social-media-platform">regulatory challenges in Brazil</a>. In September, the Brazilian Supreme Court lifted a freeze on Starlink and X&#8217;s finances after the companies paid <a href="https://www.benzinga.com/24/09/40864550/brazils-supreme-court-lifts-freeze-on-starlink-and-xs-finances-after-elon-musks-companies-cough-up-3">$3.3 million in fines</a> related to non-compliance with court orders to block certain accounts accused of spreading misinformation. This legal battle has highlighted the complexities of operating in Brazil&#8217;s regulatory environment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42054220/economics-professor-doubts-impact-of-dogecoin-inspired-elon-musk-led-department-on-federal-deficit-cites-this-as-major-concern?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Economics Professor Doubts Impact Of Dogecoin-Inspired, Elon Musk-Led Department On Federal Deficit, Cites This As Major Concern</a></li>
</ul>
Image via Shutterstock

Tech

Elon Musk's Starlink Faces New Competition As Chinese Satellite Firm Spacesail Enters Brazilian Market

The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) today announced estimated catastrophe losses for the month of October of $286 million or $226 million, after-tax, including $102 million, pre-tax, from Hurricane Milton and unfavorable reserve reestimates of $144 million, pre-tax, related to Hurricane Helene, primarily in Georgia, South Carolina and North Carolina. Total catastrophe losses for October year-to-date were $4.84 billion or $3.82 billion, after-tax.
Financial information, including material announcements about The Allstate Corporation, is routinely posted on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.allstateinvestors.com&amp;esheet=54156377&amp;newsitemid=20241121771594&amp;lan=en-US&amp;anchor=www.allstateinvestors.com&amp;index=1&amp;md5=ebb1901d3c4b2d8298664d6bd8200ed5">www.allstateinvestors.com</a>.

Allstate Announces Estimated Catastrophe Losses For The Month Of October Of $286M Or $226M, After-Tax, Including $102M, Pre-Tax, From Hurricane Milton And Unfavorable Reserve Reestimates Of $144M, Pre-Tax, Related To Hurricane Helene, Primarily In Georgia, South Carolina And North Carolina. Total Catastrophe Losses For October Year-To-Date Were $4.84B Or $3.82B, After-Tax

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) goes lower. &#8220;It's just become too <a href="https://www.benzinga.com/quote/PEP/earnings">darn hard,&#8221; he added</a>.
On Oct. 8, PepsiCo reported mixed third-quarter results and lowered its 2024 organic revenue guidance. The company reported a third-quarter net revenue decline of 0.6% year-over-year to $23.319 billion and organic growth of 1.3%, missing the consensus estimate of $23.825 billion. Adjusted EPS of $2.31 beat the consensus estimate of $2.29.
Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) makes no money, Cramer said.
On Nov. 14, Intuitive Machines reported third-quarter revenue of $58.48 million, beating analyst estimates of $50.89 million, according to Benzinga Pro. Total revenue was up 359% on a year-over-year basis. The company reported a net loss of $80.44 million, versus net income of $14.31 million in the prior year's quarter.
Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is &#8220;ok,&#8221; Cramer said. &#8220;Coterra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) is the way I like to do this thing.&#8221;
Occidental Petroleum reported quarterly adjusted earnings of $1.00 per share, beating the analyst consensus estimate of 74 cents. Quarterly revenue came in at $7.15 billion, missing the consensus estimate of $7.23 billion.
Cramer said Globe Life Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) is &#8220;fine. It's not exciting, it's not boring, it's just fine.&#8221;
On Nov. 18, Globe Life announced that its Board of Directors has approved an authorization to repurchase up to $1.8 billion of common stock under its existing stock repurchase program.
Price Action:
<ul>
<li>Intuitive Machines shares fell 3.9% to settle at $12.07 on Wednesday.</li>
<li>PepsiCo shares gained 1.3% to close at $158.74.</li>
<li>Occidental Petroleum shares gained 0.8% to close at $50.91.</li>
<li>Globe Life shares fell 0.5% to settle at $108.76 during the session.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42094434/top-3-consumer-stocks-that-are-ticking-portfolio-bombs">Top 3 Consumer Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Media

CTRA

LUNR

Jim Cramer Predicts Pepsi Goes Lower: 'It's Just Become Too Darn Hard'

CLCO

Cool Company shares are trading lower. The company reported Q3 financial results.

Supporting NASA's Artemis Campaign And Commercializing Cislunar Space With Scalable Pay-By-The-Minute Services

Intuitive Machines Partners With Johns Hopkins APL To Advance Lunar Communications And Navigation Infrastructure

Intensity Therapeutics files to sell common stock by selling stockholders

Intensity Therapeutics, Inc. (INTS) has provided an announcement. Intensity Therapeutics, Inc. successfully conducted its Annual Meeting via live w...

Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting

Intensity Therapeutics GAAP EPS of -$0.36

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Intensity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ints-stock-quote/">INTS</a>) just reported results for the second quarter of 2024.<ul><li>Intensity Therapeutics reported earnings per share of -36 cents. This was below the analyst estimate for EPS of -32 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ints-stock-earnings-intensity-therapeutics-for-q2-of-2024/">INTS Stock Earnings: Intensity Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INTS Stock Earnings: Intensity Therapeutics Misses EPS for Q2 2024

Intensity Therapeutics, Inc. (INTS) has received a new Buy rating, initiated by H.C. Wainwright analyst, Swayampakula Ramakanth. Swayampakula Ramak...

Innovative Cancer Treatment Approach Positions Intensity Therapeutics as a Compelling Investment Opportunity

Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research SAKK, a decentralized academic research institute that has been cond...

Intensity Therapeutics announces first dosing in Phase 2 trial of INT230-6

As of September 30, cash and cash equivalents totaled $2.8M, which the company expects will be sufficient to fund operations into the first quarter...

Intensity Therapeutics reports Q3 EPS (25c), consensus (30c)

Intensity Therapeutics GAAP EPS of -$0.25

Intensity Therapeutics (INTS) announced that Christian Meyer M.D., Ph.D., Assistant Professor of Oncology and lead medical oncologist for adult sar...

Intensity Therapeutics presents INT230-6 Phase 1/2 daya in Sarcoma

Intensity Therapeutics dips 5%, prices $3M offering

Press Releases

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Offerings

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Comments

Intensity Therapeutics

Intensity Therapeutics (INTS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga